CVRx

Recent Finacing

Equity

Recent Raise

$50M

CVRx develops and commercializes the Barostim Neo, a minimally invasive implantable baroreceptor neuromodulation system to treat heart failure and resistant hypertension, conducting global clinical trials and international distribution.

Founded 2001

Minnesota, United States

101-250

Publicly Traded

cvrx.com

Highlights

Focus Areas

Biotechnology

Health Care

Health Diagnostics

Medical

Medical Device

Recent Investors

Y

Financials

$184.3M

Total Raised

5

Funding rounds

16

Investors

Team

Upgrade to view the team

See the team members at CVRx.